Premium
Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective
Author(s) -
Fine BM,
Amler L
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.9
Subject(s) - clinical pharmacology , drug development , perspective (graphical) , medicine , precision oncology , clinical oncology , pharmacology , drug , oncology , computer science , cancer , artificial intelligence
The codevelopment of predictive biomarkers along with therapeutic agents, particularly in oncology, is becoming increasingly important. This approach presents both substantial opportunities and challenges. We illustrate these by reviewing some specific recent examples relating to the development of anticancer drugs targeting the HER family of cell surface receptors. We argue that ultimate success may require significant changes to the current approach to drug development. Clinical Pharmacology & Therapeutics (2009); 85 , 5, 535–538 doi: 10.1038/clpt.2009.9